Researchers at the University of California San Diego and the University of California, Riverside have published a new study mapping genome-scale RNA-protein interactions in SARS-CoV-2. By identifying unexpected binding sites across the viral life cycle, the findings reveal novel drug targets that could yield antiviral treatments less vulnerable to rapid viral evolution.
In Plain English: The Clinical Takeaway
- Targeting the Core: Instead of focusing on the rapidly changing surface spike protein, new research maps how viral proteins bind to RNA to control replication.
- Blocking the Machinery: Scientists successfully used modified nucleic acid sequences in animal and human lung cells to disrupt these interactions and significantly cut viral replication.
- Future-Proofing Antivirals: Because these internal viral mechanisms are heavily conserved across diverse coronaviruses, future treatments could theoretically withstand emerging viral variants.
Mapping Genome-Scale RNA-Protein Interactions
As today.ucsd.edu reported, investigators deployed an advanced molecular technique known as enhanced cross-linking and immunoprecipitation (eCLIP) to survey the entire SARS-CoV-2 genome. Rather than restricting their focus to previously predicted hot spots, the team mapped interactions across the whole genome to uncover unexpected sites where viral proteins bind directly to RNA.
Current clinical antivirals already demonstrate the immense value of attacking fundamental viral machinery. Remdesivir targets the RNA-dependent RNA polymerase (RdRp, designated as NSP12)—the exact enzyme responsible for copying the virus’s genetic code. Meanwhile, nirmatrelvir targets viral proteases that process long protein chains during infection. The new UC San Diego and UC Riverside findings extend this therapeutic logic by pinpointing precise binding sites for the primase cofactor (NSP8), NSP12, and the nucleocapsid (N) protein.
Among the unexpected discoveries, researchers identified an interaction between the N protein and the 5′ untranslated region at the very beginning of the viral genome. This complex RNA structure, found across numerous coronaviruses, appears to regulate translation—the essential biological process where host cellular machinery uses genetic code to synthesize proteins. Additionally, the team found an interaction between NSP12 and the RNA sequence encoding viral protein NSP3, suggesting viral RNA holds expansive regulatory roles beyond acting merely as a passive template.
“Viruses look simpler than humans at first glance, but there’s a lot of underlying complexity to their molecular biology we’re only just beginning to unravel,” said Gene Yeo, professor of cellular and molecular medicine at UC San Diego, as noted by miragenews.com.
Disrupting Viral Replication with Nucleic Acid Therapeutics
To test the functional relevance of these newly mapped boundaries, the research team introduced locked nucleic acids (LNAs)—also described as antisense oligonucleotides in reports from news.ucr.edu. These short, chemically modified nucleic acid sequences are engineered to bind specific RNA sequences, physically blocking them from interacting with essential viral proteins.
When the researchers applied these blocking agents in animal cell cultures and human lung tissue cells, they observed a significant reduction in viral replication. This validation confirms that targeting conserved viral processes can function effectively across diverse cells, organs, and host species. Such cross-species adaptability serves as an indispensable pillar for pandemic preparedness, particularly given that emerging coronaviruses frequently originate via zoonotic spillover from animals to humans.
Co-lead author Joy Xiang, assistant professor of biomedical sciences at the UC Riverside School of Medicine, emphasized the evolutionary rationale behind targeting these immutable biological structures:
“SARS-CoV-2 evolves very quickly, so it’s important to understand the really basic and essential machinery of the virus. If we target something essential that the virus depends on to function and can’t easily change, the virus is less likely to evolve away from it, which would lead to drug resistance.”
| Viral Protein Target | Interacting RNA Region | Proposed Biological Function | Experimental Disruption Tool |
|---|---|---|---|
| Nucleocapsid (N) Protein | 5′ Untranslated Region (5′ UTR) | Regulates viral translation | Locked Nucleic Acids (LNAs) / Antisense Oligonucleotides |
| NSP12 (RdRp) | RNA Encoding NSP3 | Genomic replication and regulation | Locked Nucleic Acids (LNAs) / Antisense Oligonucleotides |
| NSP8 (Primase Cofactor) | Conserved Genome Sites | Replication complex assembly | Locked Nucleic Acids (LNAs) / Antisense Oligonucleotides |
Broader Implications for Pan-Coronavirus Drug Development
The implications of mapping these conserved RNA-protein interfaces extend far beyond current COVID-19 therapeutics. Because key enzymatic proteins and RNA regulatory sequences remain structurally preserved across diverse coronavirus strains, developing small-molecule inhibitors or targeted nucleic-acid drugs against these specific motifs could offer broad-spectrum protection. Therapeutics designed around these vulnerabilities would theoretically remain potent even as individual viral variants mutate their surface spike proteins to escape antibody neutralization.
The University of California Office of the President supplied financial support for the study via its Emergency COVID-19 Research Seed Funding. The authors declared no competing financial interests in connection with the published findings.
Contraindications & When to Consult a Doctor
Because the research remains strictly in the pre-clinical phase utilizing cell cultures and animal models, no consumer therapeutics, home remedies, or over-the-counter interventions are currently available based on these specific RNA-protein targets.
References
- Regulatory sites are uncovered by genome-scale eCLIP mapping of how SARS-CoV-2 RNA interacts with NSP8, NSP12, and N.
- University of California San Diego School of Medicine.
- University of California, Riverside (UCR) School of Medicine. UCR News, 2026.
